Navigation Links
Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor
Date:11/27/2012

of the Worldwide Business Development division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry. For more information, please visit www.pfizerventureinvestments.com 

About Rhythm (www.rhythmtx.com)
Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm is developing the ghrelin peptide agonist, RM-131, for the treatment of diabetic gastroparesis and other GI functional disorders, and the MC4R peptide agonist, RM-493, for obesity and diabetes. Rhythm investors include MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen, and Pfizer Venture Investments. The company is based in Boston, Massachusetts.

Contact:
Bart Henderson
President
(857) 264-4281
bhenderson@rhythmtx.com


'/>"/>
SOURCE Rhythm
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Rhythm Names Lex Van der Ploeg Chief Scientific Officer
2. Rap music powers rhythmic action of medical sensor
3. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
4. Rhythmic firing of nerve cells involved in bodys movements
5. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
6. UV Flu Technologies Expands Its International Footprint
7. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
8. Ansell Limited Expands Korean Presence
9. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
10. Groundbreaking National Program to Reverse Obesity Expands to 50 Locations
11. Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... N.J. , May 30, 2015  Data ... 2 MMY2002 (SIRIUS) trial show treatment with single-agent ... – achieved an overall response rate (ORR) of ... an independent review committee, in heavily pre-treated patients ... the pre-specified subgroups based on age, prior lines ...
(Date:5/29/2015)... 29, 2015 BerGenBio AS ("BerGenBio" ... that an abstract on the latest data on BGB324, ... Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking ... published in conjunction with the 2015 American Society of ... , May 29 - June 2, 2015. ...
(Date:5/29/2015)... London, UK (PRWEB) May 29, 2015 ... Co., Ltd. (Chem-Report ) signed a partnership agreement ... is now authorised to distribute and sell research ... Assistant Manager at Partners Department, commented upon the ... creating reports on key petroleum and chemical markets ...
(Date:5/29/2015)... , May 29, 2015  Caris Life ... on fulfilling the promise of precision medicine, today ... that demonstrate the clinical utility of Caris Molecular ... profiling service, in helping to identify targeted treatment ... In each of the studies, results of which ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6
... DiversityInc, a leading publication on diversity and business, has recognized University Hospitals ... listing. , , , ... ranked the Top 50 Companies for Diversity based on results from an extensive questionnaire. ... , , ...
... Germany , June 15, 2010 Pieris AG,announced today the ... program, PRS-050, an anti-VEGF Anticalin. The trial is an,open-label, dose-escalating evaluation of ... sites in, Germany , the trial is underway and patients from the ... , ...
... ... upgraded SaaS application for the life sciences industry that incorporates distinctive features and ... ... new-media solutions for the life sciences industry, today announced the release of Version ...
Cached Biology Technology:Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation 2Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound 2Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 2Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 3
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... age to fly the nest, but it,s hormones that actually control ... University of Leeds. The study published online in ... main trigger which causes chicks to leave the nest and embark ... studying a colony of Manx Shearwaters ( Puffinus puffinus ), on ...
... One of cancer,s most frightening characteristics is its ability to ... cancer, including the skin cancer known as melanoma, tailored drugs ... only partial, temporary responses in patients. One of the burning ... remains: how does cancer evade drug treatment? New research ...
... you are a primate crossing the jungle. Using human street ... required to navigate a forest using different strategies and found ... was presented at the Society for Experimental Biology,s meeting in ... help us to understand why orangutans spend most of their ...
Cached Biology News:Hormones dictate when youngsters fly the nest, says new research 2Tumor microenvironment helps skin cancer cells resist drug treatment 2Tumor microenvironment helps skin cancer cells resist drug treatment 3Tumor microenvironment helps skin cancer cells resist drug treatment 4
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Kit provides a positive selection for creating ... expression in insect cells. The kit improves ... baculoviruses by eliminating the time-consuming steps of ... AcNPV genome with a portion of the ...
... General description: Dish uses include large-scale ... Compatible with PBA Flexys TM automated ... number is a new product number, created ... showing no availability yet, please order under ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Biology Products: